AZD9574 + temozolomide

AZD9574 + temozolomide is a combination of two drugs: AZD9574, a brain-penetrant, selective inhibitor and trapper of poly(ADP-ribose) polymerase 1 (PARP1), and temozolomide, an oral alkylating agent used primarily in the treatment of gliomas and other cancers. AZD9574 inhibits PARP1-mediated DNA repair processes, increasing sensitivity of cancer cells—particularly those with homologous recombination repair deficiencies—to cytotoxic damage. Temozolomide adds alkyl groups to DNA, causing irreparable damage and cell death, especially in tumors with suppressed repair pathways. This combination is currently being investigated for synergistic efficacy in IDH-mutant glioma and other selected solid tumors, making use of the DNA damage amplification through dual-compromised repair mechanisms. AZD9574 is developed by AstraZeneca and is in early-phase clinical trials for use in advanced solid malignancies, including gliomas, breast, ovarian, pancreatic, and prostate cancers[1][2][3][5][7].

Other names

AZD9574 plus temozolomideAZD-9574 plus temozolomideAZD 9574 plus temozolomideAZD9574 and TMZAZD-9574 and TMZAZD 9574 and TMZ